Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Capital Expenditures (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Capital Expenditures for 9 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 70.07% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Dec 2025, down 40.28% year-over-year, with the annual reading at $9.5 million for FY2025, 40.28% down from the prior year.
  • Capital Expenditures for Q4 2025 was $1.5 million at Denali Therapeutics, up from -$1.4 million in the prior quarter.
  • The five-year high for Capital Expenditures was $10.1 million in Q3 2023, with the low at -$2.2 million in Q2 2023.
  • Average Capital Expenditures over 5 years is $2.5 million, with a median of $2.2 million recorded in 2024.
  • Peak annual rise in Capital Expenditures hit 27475.68% in 2023, while the deepest fall reached 1168.12% in 2023.
  • Over 5 years, Capital Expenditures stood at $3.1 million in 2021, then plummeted by 61.35% to $1.2 million in 2022, then skyrocketed by 89.41% to $2.2 million in 2023, then surged by 127.83% to $5.1 million in 2024, then tumbled by 70.07% to $1.5 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $1.5 million, -$1.4 million, and $8.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.